The present invention relates to a composition comprising, separately or together, methotrexate (MTX) and (E)-N-trans-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium acetate (AP1189), or pharmaceutically acceptable derivatives thereof, for use in a method of treating an arthritis disease, such as rheumatoid arthritis.
Provided is a composition comprising a phenyl pyrrole aminoguanidine derivative for use in a method of treating cardiovascular disease, hypertension and/or atherosclerosis.
Provided is a therapy comprising a compound of formula (I), such as AP1189, and methotrexate for the treatment of rheumatoid arthritis in subjects having active systemic inflammation.
Provided is a therapy comprising a compound of formula (I), such as AP1189, and methotrexate for the treatment of rheumatoid arthritis in subjects having active systemic inflammation.
The present disclosure relates to crystalline forms of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium salts having high solubility. The disclosure also relates to use of said crystalline forms in medicine.
The present disclosure relates to a crystalline form of 2-{3-[1-(2-nitrophenyl)-1H-pyrrol- 2-yl]prop-2-en-1-ylidine}hydrazine-1-carboximidamide having high solubility at acidic conditions. The disclosure also relates to use of said crystalline form in medicine.
C07D 207/325 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
Provided is a composition comprising a phenyl pyrrole aminoguanidine derivative for use in a method of treating cardiovascular disease, hypertension and/or atherosclerosis.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
The present disclosure relates to crystalline forms of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium salts having high solubility. The disclosure also relates to use of said crystalline forms in medicine.
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 9/00 - Medicinal preparations characterised by special physical form
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient
Provided is a composition comprising a phenyl pyrrole aminoguanidine derivative for use in a method of treating viral disorders and diseases, including symptomatic viral disorders and diseases, including symptomatic COVID-19.
The present disclosure relates to crystalline forms of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium salts having high solubility. The disclosure also relates to use of said crystalline forms in medicine.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07C 51/00 - Preparation of carboxylic acids or their salts, halides, or anhydrides
C07C 309/29 - Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
C07D 207/335 - Radicals substituted by nitrogen atoms not forming part of a nitro radical
15.
SALTS OF PHENYL PYRROLE AMINOGUANIDINE AND POLYMORPHS OF PHENYL PYRROLE AMINOGUANIDINIUM SALTS
NN-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium salts having high solubility. The disclosure also relates to use of said crystalline forms in medicine.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07C 51/00 - Preparation of carboxylic acids or their salts, halides, or anhydrides
C07C 233/83 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an acyclic saturated carbon skeleton
C07C 309/29 - Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
The present invention relates to a composition comprising, separately or together, methotrexate (MTX) and (E)-N-trans-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium acetate (AP1189), or pharmaceutically acceptable derivatives thereof, for use in a method of treating an arthritis disease, such as rheumatoid arthritis.
Provided is a composition comprising a phenyl pyrrole aminoguanidine derivative for use in a method of treating viral disorders and diseases, including symptomatic viral disorders and diseases, including symptomatic COVID-19.
Provided is a composition comprising a phenyl pyrrole aminoguanidine derivative for use in a method of treating viral disorders and diseases, including symptomatic viral disorders and diseases, including symptomatic COVID-19.
Provided is a composition comprising a phenyl pyrrole aminoguanidine derivative for use in a method of treating kidney disease, such as nephrotic syndromes.
ENtranstrans-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium acetate (AP1189), or pharmaceutically acceptable derivatives thereof, for use in a method of treating an arthritis disease, such as rheumatoid arthritis.
The present invention relates to a composition comprising, separately or together, methotrexate (MTX) and (E)-N-trans-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium acetate (AP1189), or pharmaceutically acceptable derivatives thereof, for use in a method of treating an arthritis disease, such as rheumatoid arthritis.
Provided is a composition comprising a phenyl pyrrole aminoguanidine derivative for use in a method of treating kidney disease, such as nephrotic syndromes.
Provided is a composition comprising a phenyl pyrrole aminoguanidine derivative for use in a method of treating kidney disease, such as nephrotic syndromes.
The present invention relates to phenyl pyrrole aminoguanidine derivatives of the general formula (I): (I) including tautomeric forms thereof, wherein n is 1, 2 or 3; or a pharmaceutically acceptable salt thereof. The present invention further relates to the use of such phenyl pyrrole aminoguanidine derivatives for the treatment of diseases associated with the melanocortin receptors or related systems, e.g. the melanocyte stimulating hormones.
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
C07D 207/30 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
patents
